News

The application for TUKYSA approval was reviewed by Swissmedic as part of Project Orbis, an initiative of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence

In the late-stage trial called IKEMA, Sarclisa, when added to carfilzomib and dexamethasone, met the primary endpoint by delivering significantly prolonged progression-free survival compared to standard of care

“We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease,” said Michael Goldstein, MD, MBA, Chief Medical Officer. “We believe that the intracanalicular

Earlier this month, the FDA has completed its review of Moderna’s investigational new drug (IND) application for mRNA-1273 to conduct Phase 2 study, which is expected to be

Favipiravir is approved in Japan as the anti-influenza drug Avigan. With FFTC providing support through donated drug product, the phase 2 study will be conducted at long-term care

In this regard, the Texas-based Acer Therapeutics has signed a research collaboration agreement with NCATS, which is one of the National Institutes of Health (NIH) in the US.

“RMAT designation is another important regulatory milestone for CTX001 and underscores the transformative potential of a CRISPR-based therapy for patients with severe hemoglobinopathies,” said Samarth Kulkarni, Ph.D., Chief

The company has secured approval from the Drugs Controller General of India (DCGI) to begin the trial with Favipiravir at the end of April. Favipiravir is a generic

According to jCyte, treatment with jCell is a minimally-invasive intravitreal injection, which can be carried out in an ophthalmologist’s office with topical anesthetic. The entire procedure is said